Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Rusfertide acetate by Protagonist Therapeutics for Polycythemia Vera: Likelihood of Approval
Rusfertide acetate is under clinical development by Protagonist Therapeutics and currently in Phase III for Polycythemia Vera. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's Rusfertide acetate?
Rusfertide acetate is a synthetic peptide commercialized by Takeda Pharmaceutical, with a leading Phase III program in Polycythemia Vera. According...